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NKT cells depend on SAP
 
An intracellular adaptor protein is indispensable for the
development of natural killer T (NKT) cells, according to
Pasquier et al. (page 695). The loss of these cells might
contribute to the genesis of a lethal immunodeficiency
syndrome.
The adaptor protein in question—SAP (SLAM-associated
protein)—is expressed in T, NK, and NKT cells and responds
to SLAM family receptors by recruiting and activating the
downstream tyrosine kinase Fyn. Fyn was known to be re-
quired for NKT cell development in the thymus, but the
upstream cell surface signals remained unknown.
Pasquier and colleagues now implicate the SLAM family of
receptors in NKT cell development by showing that the loss of
SAP results in a complete absence of NKT cells in both mice
and humans. SAP-transmitted signaling events were uniquely
required for the development of NKT cells, as conventional T
 
Inﬂammation control gets ﬁshy
 
A new study explains how a diet high in 
oily fish like salmon and mackerel 
improves inflammatory conditions, 
particularly in combination with low 
doses of aspirin. On page 713, Arita 
et al. decipher the structure of an 
antiinflammatory lipid in humans that 
is derived from an essential fatty acid 
in fish oil.
Fatty fish contain large amounts of 
omega-3 fatty acids—diet-derived 
essential fatty acids known to benefit 
patients with cardiovascular disease and 
 
cells and NK cells developed normally in the absence of SAP.
The need for SAP-mediated signals may reflect the unique
requirements for positive selection of NKT cells in the thymus.
Whereas conventional T cells interact with thymic epithelial
cells for selection, NKT cells must interact with CD1d-
expressing thymocytes via their invariant T cell receptors.
This unique interaction might also provide the required
SLAM-mediated signals.
In an intriguing twist, mutations in SAP cause a fatal disease
called X-linked lymphoproliferative syndrome (XLP), which
is characterized by uncontrolled Epstein-Barr virus (EBV) in-
fections and B cell lymphomas. The loss of SAP impacts the
function of multiple cell types including NK cells and T cells,
but based on the current study, NKT cells may also contribute
to XLP. Studying NKT cell activation during human EBV
infection may give clues about why the lack of SAP, which
results in so many immune cell defects, would preferentially
increase susceptibility to only one type of virus.
 
arthritis. This group recently identified 
a new class of aspirin-triggered 
bioactive lipids, called resolvins, the 
activity of which may in part explain 
the beneficial effects of omega-3 fatty 
acids. Resolvins are synthesized from 
the omega-3 fatty acids by cellular 
enzymes and are potent counter-
regulators of inflammation in mice. The 
main bioactive component of this class 
of lipids was identified in mice and 
named resolvin E1.
Recent clinical trials showing that 
omega-3 fatty acids combined with 
aspirin reduced the risk of heart attack 
prompted the authors to look for 
resolvin E1 in humans. They have now 
identified this lipid in plasma taken from 
volunteers given omega-3 fatty acids 
and aspirin, deciphered its complete 
stereochemical structure, and identified 
its receptor.
Human resolvin E1, the authors 
show, binds to a G protein–coupled 
receptor called ChemR23 that is 
expressed on leukocytes, and inhibits 
the migration of these cells to sites of 
inflammation. Resolvin E1 might also 
affect adaptive immunity in response to 
pathogens, as it reduced the production 
of interleukin-12 by dendritic cells and 
inhibited their migration to T cell areas 
of the spleen in mice.
In previous studies, aspirin promoted 
the cyclooxygenase-2 (COX-2)–
dependent conversion of omega-3 
fatty acids to a precursor of resolvin E1. 
COX-2 also converts arachidonic acid, 
another essential fatty acid, into 
proinflammatory prostaglandins. COX-2 
inhibitors, designed to block this 
proinflammatory pathway, have had 
negative cardiovascular side effects. 
The authors thus suggest that inhibition 
of vascular COX-2 might also block 
the synthesis of resolvin E1, which 
would eliminate an important 
antiinflammatory pathway. The structure of resolvin E1, a potent antiinflammatory lipid derived from omega-3 fatty acids.
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Refusing to be suppressed
 
On page 737, Fahlén et al. show that colitis-inducing effector T cells that
cannot respond to the suppressive cytokine TGF-
 
 
 
 refuse to be controlled by 
regulatory T (T reg) cells.
Naturally occurring T reg cells suppress the activity of effector CD4
 
 
 
 T cells and 
are essential for the prevention of autoimmune disease and chronic inflammation. 
TGF-
 
 
 
 appears to be required for T reg cell activity, but determining which cells 
produce TGF-
 
 
 
 and which cells respond to it has proven difficult.
Fahlén and colleagues now attempt to define the role of TGF-
 
 
 
 in a mouse model 
of T cell–induced colitis. In this model, colitis can be reversed when CD4
 
 
 
CD25
 
 
 
 T reg 
cells are provided along with the disease-inducing effector cells. The authors showed 
that wild-type T reg cells inhibited the development of colitis induced by wild-type 
effector T cells but failed to prevent disease caused by effector T cells bearing a 
signaling-defective TGF-
 
 
 
 receptor. This demonstrated that effector cells had to be 
responsive to TGF-
 
 
 
 to be controlled by T reg cells. The T reg cells were not required as 
a source of TGF-
 
 
 
, as T reg cells from TGF-
 
 
 
–deficient mice were also able to suppress. 
Thus, T reg cells must be prompting another cell type to produce TGF-
 
 
 
, or may be 
producing a regulatory signal that operates cooperatively with TGF-
 
 
 
.
But did the T reg cells also require TGF-
 
 
 
 signals to induce suppression, as several 
previous studies had shown? The authors found no differences between the T reg 
populations in mice with normal or signaling-defective TGF-
 
 
 
 receptors, and lymph 
node–derived T reg cells from both mice suppressed colitis.
Transfer of splenic T reg cells with mutant TGF-
 
 
 
 receptors, however, 
triggered rather than inhibited colitis. The authors suggest that this can be 
explained by contaminating effector cells that are also mutant for the TGF-
 
 
 
 
receptor and, therefore, cannot be controlled by the inhibitory signal. Thus, the 
requirement for TGF-
 
 
 
 in T reg cell suppression appears to be dictated primarily 
by the effector cells.
T reg cells cannot control colitis if the disease-
inducing effector T cells are unresponsive 
to TGF- .
 
Out with the old, in with the new
 
Muraro et al., reporting on page 805, use stem
An MS lesion (arrow) was 
resolved two years after 
stem cell transplantation.
 
cell transplants to suppress active multiple scle-
rosis (MS), and then show that the treatment in-
creased  the number of naive T cells at the
expense of the memory T cells that are associated
with disease.
Intense immunosuppression followed by
stem cell transplantation has been shown to slow
or stop the formation of new brain lesions in up
to 95% of patients with aggressive MS. Yet it
has been controversial and rarely used, mainly
because immunosuppression is risky and because
nothing was known about how transplantation
induced remission. One proposed theory
was that transplantation might change the
composition of the T cell pool and bias it
away from autoreactivity.
Muraro and colleagues now provide the first
evidence that stem cell transplantation allows
patients to regenerate a new repertoire of T cells
that are less activated and more diverse than
their pretransplant repertoires. This suggests that
 
many of the disease-causing T cells—most of
which have a memory phenotype—were elim-
inated by the treatment.
However, concrete proof that autoreactive
T cells are reduced or eliminated is difficult to
obtain, partly because the specificities of the
autoreactive T cells that invade the central
nervous system are not well defined.
The difficulty in assessing the basis for
treatment success is one problem. Another
is the possibility that autoreactive cells will
reemerge from the pool of transferred stem
cells. The authors agree that these cells
could eventually come back, but hope that
resetting the immune system may improve
the quality of life for patients with an other-
wise poor prognosis.
They emphasize, however, that this intense
therapy is probably only suited to a subset of
MS patients who have active and aggressive
disease and that its implementation will require
careful patient selection.
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